Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Part D plans participating in the model are required to place all model drugs on the same formulary tier, cover all medically accepted indications for model drugs, and apply the same cost sharing to all indications
In June, a paper in JAMA Ophthalmology looked at age-related macular degeneration in people with Type 2 diabetes who were taking GLP-1 drugs
Step four: consider compounded alternatives If brand name medications are not financially viable, compounded versions offer a significantly lower-cost pathway to continued treatment
Responses to tickets are described as slow, unhelpful, or non-existent in some cases
